image credit: Unsplash

Single dose of J&J’s Ad26.COV2.S vaccine effective against SARS-CoV-2 including in South Africa variant

April 26, 2021

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic emerged in late 2019 in Wuhan, China, and has led to high morbidity and mortality worldwide, with newer, more infectious variants rapidly emerging and infecting more people in several countries.

Thanks to a collaborative effort by scientists across the world, many vaccines have been developed to prevent SARS-CoV-2 infection with unprecedented speed.

One of these vaccines, the Ad26.COV2.S vaccine by Johnson & Johnson and Janssen, is a recombinant, replication-incompetent human adenovirus type 26 vector that encodes full-length SARS-CoV-2 spike protein in a prefusion-stabilized conformation.

Read More on Medical News